222 results about "Hematological sample" patented technology

The presence of oxygen or red blood cells in a sample applied to an electrochemical test strip that makes use of a reduced mediator is corrected for by an additive correction factor that is determined as a function of the temperature of the sample and a measurement that reflects the oxygen carrying capacity of the sample. The measured oxygen carrying capacity can also be used to determine hematocrit and to distinguish between blood samples and control solutions applied to a test strip.

Devices and methods for performing a point of care blood, cell, and/or pathogen count or a similar blood test. Disclosed herein are systems that can be used to provide rapid, accurate, affordable laboratory-quality testing at the point of care. The systems described herein are capable of imaging and counting individual cells in a prepared cell sample (e.g., a peripheral blood smear or a blood sample prepared in a microfluidic device) or another prepared cell-containing sample without the need for a microscope or other expensive and cumbersome optics. The systems described herein are designed to eliminate or replace expensive, centralized clinical testing equipment and technical personnel. Such systems may include automated data reporting and decision support.

There is provided a method for classifying and counting leukocytes with abnormal DNA amount, which comprises: (1) a step of staining cells in a sample obtained from a hematological sample by treatment with a hemolytic agent to lyse erythrocytes, with a fluorescent dye which can make a difference in the fluorescence intensity at least among mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes; (2) a step of introducing the sample containing the stained cells into a flow cytometer to measure scattered light and fluorescence of the respective cells; (3) a step of classifying leukocytes and coincidence cells/platelet clumps utilizing a difference in the intensity of a scattered light peak and a difference in the scattered light width; (4) a step of classifying and counting mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes, utilizing a difference in the scattered light intensity and a difference in the fluorescence intensity of leukocytes classified in the step (3).

Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput.

Blood cells of interest are readily distinguishable from other blood cells and look-a-like particles found in a blood sample by their back-scatter signature. A preferred method for differentiating platelets in a blood sample is to irradiate the cells and particles, one at a time, with a beam of radiation, and to detect back-scattered (reflected) radiation using a plurality of optical fibers to transmit the back-scattered radiation to a high-gain photodetector, e.g. a photomultiplier tube. Preferably, the back-scatter signal so obtained is combined with a second signal representing, for example, either the level of forward-scatter within a prescribed, relatively narrow angular range, or the level of side-scattered radiation, or the level of attenuation of the cell-irradiating beam caused by the presence of the irradiated cell or particle in the beam, or the electrical impedance of the irradiated cell or particle, to differentiate the cells of interest. The method and apparatus of the invention are particularly useful in differentiating platelets and basophils in a blood sample.

The invention provides a measuring method which can classify and count myeloblast more precisely without influence of other component in a sample including platelet aggregation in measurement of a blood sample with a flowcytometry, wherein damage is given to a cell membrane of erythrocyte and mature leukocyte contained in a hematological sample, a hemocyte in which a cell membrane is damaged is constricted, and this is dyeing-treated with a fluorescent dye which can stain a nucleic acid to obtain a sample, the sample is measured with a flowcytometer, and a cell contained in a first cell group containing myeloblast, which is specified based on forward scattered light information and side scattered light information, and contained in a second cell group containing myeloblast, which is specified based on forward scattered light information and fluorescent information, is counted as myeloblast. The invention further provides a measuring device comprising following systems: a sample treating system, an information acquisition system, a first specific system, a second specific system and a counting system.

A dry test strip layer for filtering red blood cells includes a Borosilicate Glass Fiber layer and lectin, impregnated in the borosilicate layer, such that the dry test strip is configured to filter red blood cells from a blood sample.

A method for classifying and counting leukocytes comprises the steps of: (1) adding to a hematological sample the following fluorescence-labeled antibodies labeled with fluorescent dyes which emit fluorescences distinguishable from each other; (a) a first fluorescence-labeled antibody (1st antibody) which bonds specifically to leukocytes, (b) a second fluorescence-labeled antibody (2nd antibody) which bonds to at least one kind of neutrophilic cells, and (c) a third fluorescence-labeled antibody (3rd antibody) which bonds to at least one kind of immature granulocytic cells, in order to stain leukocytic cells in the sample, and removing erythrocytes from the sample; (2) analyzing the resulting sample using a flow cytometer to measure at least one scattered light signal and three separate fluorescence signals; (3) defining a group of granulocytic cells on the basis of intensity of the scattered light and intensity of fluorescence from the 1st antibody; (4) defining neutrophilic cells in the defined group of granulocylic cells on the basis of the intensity of the fluorescence from the 1st antibody and intensity of fluorescence from the 2nd or 3rd antibody; (5) classifying the defined group of the neutrophilic cells into groups of neutrophilic cells different in degree of maturity on the basis of the intensity of the fluorescence from the 2nd antibody and the intensity of the fluorescence from the 3rd antibody, and counting the number of cells in each of the groups.

This invention is concerned with a method for evaluating the dynamic biological state of a patient, said method, which involves measuring several elements or substances contained in the blood and interpreting results of the measurements carried out, comprising the following steps (1°) taking a sample of blood from the patient to be examined; (2°) determining hematic substances serving as metabolic and/or tissue parameters; (3°) measuring, on the basis of the determination of step (2°), the totality or part of indexes J1 to J157 defined in the disclosure; and (4°) comparing at least part of said indexes J1 to J157 with similar values obtained at steps (2°) and (3°) on subjects already identified as healthy, to dynamically assess the biological state of the patient to be examined. This invention is also concerned with a software product for executing on a computer steps (3°) and (4°).

A method for discriminating and quantifying platelets within an analyzed blood sample involves initially diluting the blood sample with a ghosting reagent that causes a change in the index of refraction of the cell. Owing to the change in the index of refraction, light scattered from the ghosted red blood cells will be substantially reduced relative to light scattered from platelets. This results in locations of platelets within a scatterplot of the analyzed blood sample to fall within a region distinguishable from those containing normal red blood cells, fragmented red blood cells, and microcytic red blood cells.

A method for indentifying red cell fragments is used for blood cell analysis with cell counting by the resistance method, and comprises the following steps: A. counting white blood cells in a blood sample, drawing a white blood cell column diagram, and recording the full width at half maximum of each particle pulse during the process of particle pulse signal identification; B. locating an area A with possible existence of red cell fragments and an area B without any red cell fragments on the white blood cell column diagram, and determining whether the existence of red cell fragments interfering with white blood cell counting is true in the area A according to the comparison between the distribution of the full width at half maximum of particle pulse in the area A and in the area B; and C. in the case of disturbance caused by red cell fragments, determining the position, in which the interference peak of red cells ends, and correcting the count value of white blood cells according to the ending position of the interference peak of the red cells. The method achieves the effect of improving the accuracy of the result of white blood cell counting and the accuracy of white blood cell classification.

The invention relates to the measurement for the lipid molecule content in a human blood sample as well as the preparation and the application of a colon cancer or rectum cancer diagnosis reagent kit, in particular to the extraction of lipid molecules in a human blood sample and the content measurement thereof as well as the definition of colon cancer or rectum cancer lipid molecule marks. In addition, the invention also discloses the details about the detection of a few colon cancer or rectum cancer lipid molecule marks in a blood sample and provides a reagent kit which is formed according to the lipid molecule marks and used for colon cancer or rectum cancer diagnosis. According to the content of the lipid molecule marks in the sample, the possibility for a patient suffering the colon cancer or rectum cancer can be diagnosed from the sample through special calculation and analysis, and the invention also provides a new means for the healing efficacy analysis in the colon cancer or rectum cancer treatment.

The invention provides methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies. A large panel of differentially methylated regions (DMRs) have been identified. Certain of these DMRs are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA, whereas others are hypermethylated in adult female blood DNA and hypomethylated in fetal DNA. Moreover, DMRs that are hypomethylated in adult female blood DNA and hypermethylated in fetal DNA have been shown to accurately predict a fetal aneuploidy in fetal DNA present in a maternal blood sample during pregnancy. In the methods of the invention, hypermethylated DNA is physically separated from hypomethylated DNA, preferably by methylated DNA immunoprecipitation.

Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In some embodiments, the ex vivo testing is measured using a recently extracted patient hematological samples. In other embodiments, the efficacy is measured ex vivo using an automated flow cytometry platform. For example, by using an automated flow cytometry platform, the evaluation of hundreds, or even thousands of drugs and compositions, can be made ex vivo. Thus, alternative polytherapy treatments can be explored. Non-cytotoxic drugs surprisingly induce apoptosis selectively in malignant cells ex vivo. In some embodiments, the methods described herein comprise evaluating non-cytotoxic drugs.

Methods and apparatus are disclosed for determining new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. The inventive methods and apparatus provide an International Normalization Ratio (INR) based on a coagulation reaction with a blood sample of a living being. Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or an ISI, and may be carried out with the patient sample and a coagulation reagent, where the coagulation reagent may be selected from a number of coagulation reagents. One embodiment provides an INRs value which is determined from a prothrombin time (PT or T1) of a patient blood sample and a theoretical end of test time (TEOT), where a theoretical clotting area is used to determine the INRs value according to the expression, INRs=T1*TEOT*MUL, where MUL is a multiplier that takes into account pixel parity and sampling times. The INRs may be used to determine a course of treatment for a patient or other living being without regard to the specific coagulation regent used to generate the coagulation data (e.g., time and optical activity values).

This present invention relates generally to devices, systems, and methods for performing bioimaging at the microscopic scale and, more particularly, to devices and systems including a disposable testing device configured to perform bioimaging at the microscopic scale, and methods of performing the bioimaging using the disposable testing device. In some aspects, a testing device is provided for imaging blood cells in a blood sample. The testing device having a sample entry port for receiving the blood sample; a sample testing conduit fluidically connected to the sample entry port, the sample testing conduit including: (i) a planar member, (ii) a transparent planar member, and (iii) a plurality of spacer elements having an average spacer height and disposed between the planar member and the transparent planar member; and an imager chip forming at least a portion of the planar member.

Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a non-small-cell lung cancer patient, head and neck squamous cell carcinoma or colorectal cancer patient has likely developed a non-responsiveness to treatment with a drug targeting an epidermal growth factor receptor pathway. As the methods of this disclosure require only simple blood samples, the methods enable a fast and non-intrusive way of measuring when drugs targeting the EGFR pathway cease to be effective in certain patients. This discovery represents the first known example of true personalized selection of these types of cancer patients for treatment using these classes of drugs not only initially, but during the course of treatment.

The invention discloses a method and a kit for detecting circulating tumor cell antigens in peripheral blood through electrochemical luminescence detection. The method comprises the steps of transferring a blood sample into a centrifuge tube by use of an enriched buffer solution, metering to realize constant volume, and mixing uniformly; centrifuging, discarding supernatant, splitting red cells and reselecting the cells; adding an enriched buffer solution and re-suspending the cells; centrifuging, discarding supernatant, adding the enriched buffer solution and EpCAM antibody magnetic beads, mixing uniformly and incubating; placing the centrifuge tube on a magnetic base in a standing manner and removing liquid supernatant; adding a cleaning buffer solution and washing to obtain a magnetic microsphere system; adding a Ru(bpy)2(dcbpy)NHS-tumor cell antibody into the magnetic microsphere system, mixing uniformly and incubating; placing the centrifugal tube on the magnetic base in the standing manner and removing liquid supernatant; adding the cleaning buffer solution and washing; and placing in an electrochemical luminescence detector and measuring the content of the tumor cell surface antigens. The method can be used for remarkably enlarging the detection range and improving the detection sensitivity of the circulating tumor cell antigens in the peripheral blood, and is rapid, accurate and slight in harm.

The invention provides lung cancer CTCs (Circulating Tumor Cells) capturing and activity detection and analysis methods and application thereof. On the basis of negative enriched lung cancer CTCs, by capturing on the lung cancer CTCs, the lung cancer CTCs are captured on a filter membrane; by carrying out combined detection on a nuclear morphometry and expression quantities of three specific mRNAs, the lung cancer CTCs are identified; suspected CTCs captured from each blood sample are subjected to cell nucleus size and morphological feature analysis; a TTF1 mRNA and a pan-CK mRNA are combined to identify whether the suspected CTCs are TTF1 positive lung cancer CTCs, so that according to a case whether MKI67 mRNA expression is positive, the suspected CTCs are classified as TTF1 positive lung cancer CTCs with the proliferative activity or TTF1 positive lung cancer CTCs without the proliferative activity. The detection method provided by the invention is high in sensitivity and high in specificity, the number of the TTF1 positive CTCs in peripheral blood of a lung cancer patient can be efficiently captured and counted; the activity of the TTF1 positive CTCs can be detected; whether each cell has the proliferative activity or not can be analyzed out.

The invention relates to a device and a method for separating red cells from a blood sample and a device and a method for detecting analyzed substances in the blood sample. The method for separating red cells from the blood sample comprises the following steps: making the blood sample contact receptors of fibrin in a combined blood sample; and separating out the receptors of the fibrin from the blood sample. The device for detecting the analyzed substances in the blood sample comprises a carrier which comprises a detection area, and the device is characterized in that the upstream of the detection area comprises the receptors of the fibrin in the combined blood sample. The red cells in the blood sample can be effectively separated by using the devices and the methods so as to reduce the obstruction effect of the red cells on liquid flow and the interference of the red cells on a response background. The methods and the devices do not cause adverse effects on the detection results.

An insulin infusion device and a related operating method are disclosed. The method obtains a blood glucose (BG) measurement of a blood sample from a user, displays the BG measurement on a display element of the infusion device, and receives a confirmation input that indicates user acceptance of the displayed BG measurement. In response to the confirmation input, a glucose sensor calibration routine is automatically initiated, and an insulin bolus calculation is automatically initiated. The calibration routine and the bolus calculation use the confirmed BG measurement. The method continues by controlling delivery of insulin, in accordance with the calculated insulin bolus, from a fluid reservoir of the insulin infusion device. The sensor calibration routine and the insulin bolus calculation are both performed without any additional user involvement or interaction with the user interface other than the user acceptance of the displayed BG measurement.

The invention relates to a method and a related kit for detecting c-MET/CEP7 gene status based on rare cells, wherein the method comprises the following steps: 1. acquiring a blood sample or a body fluid sample, wherein the sample includes a mixed cell population of circulating tumor cells or other rare cells and white blood cells; 2. diluting the sample by virtue of a buffer solution, removing plasma and recovering CTC or other rare cells; 3. cracking by virtue of a red blood cell lysis buffer, removing red blood cells and recovering CTC or other rare cells; 4. recovering cells with magnetic particles coated with related anti-human leucocyte antigens and antibodies, uniformly mixing and breeding, and fully combining so as to form a magnetic particle-white blood cell mixture; 5. isolating the magnetic particle-white blood cell mixture from other cells so as to obtain a mixed cell population containing CTC or other rare cells and a few of white blood cells; and 6. by virtue of a method combining immunofluorescence cytochemistry and fluorescence in-situ hybridization, determining the status of c-MET/CEP7, and simultaneously identifying CTC or other rare cells.